The paper reports a Martinican woman who at 31 (after 3 years of progressive gait ataxia and dysarthria) had pontocerebellar atrophy with hot cross bun sign on MRI, acellular CSF without oligoclonal bands, and high-titer anti-Purkinje cell antibodies (serum 1/32,000; CSF 1/1,000) later characterized as anti-ITPR1 .
Immunotherapy (methylprednisolone, plasma exchange, IVIg) failed; she stabilized severely disabled. She carried a pathogenic germline BRCA1 mutation, and 11 years after onset, surveillance mammography found a bifocal grade I, ER+/PR+/Her2+ ductal carcinoma with nodal metastases; both tumor and metastatic nodes expressed ITPR1. The authors infer the cerebellar autoimmunity was paraneoplastic, but explicitly acknowledge that with only 4 prior published anti-ITPR1 ataxia cases and no other tumor association, no conclusion about cancer association is possible.
Reported observations: clinical course, titers, imaging, tumor pathology, and BRCA1 status are documented in detail. Author interpretation: the paraneoplastic label is an inference from tumor ITPR1 expression plus temporal sequence; the patient was in tumor remission with unchanged neurology at 6 months, so no causal test occurred. BGPT inference: 11 years is far longer than typical PCD-to-cancer intervals reported in the cited Euronetwork series, and ITPR1 is broadly expressed in normal tissues, so tumor expression alone is weak evidence. Possible confounders include the BRCA1-driven breast cancer risk being independent of the ataxia, and coincidence. The long latency also raises the reverse-causality question: could decades of autoimmunity be unrelated to a genetically predisposed cancer? No post-treatment antibody titer data are given, which would be the natural falsification test. Strengths: rigorous negative tumor screening before cancer, objective immunopathology, and full serial clinical data.
Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.